Last reviewed · How we verify
palonosetron, dexamethasone, and 0.9% NaCl
palonosetron, dexamethasone, and 0.9% NaCl is a antiemetic combination Small molecule drug developed by Sixth Affiliated Hospital, Sun Yat-sen University. It is currently in Phase 3 development for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). Also known as: double therapy.
Palonosetron blocks serotonin 5-HT3 receptors, while dexamethasone has anti-inflammatory and antiemetic effects, and 0.9% NaCl provides hydration and electrolyte balance.
Palonosetron blocks serotonin 5-HT3 receptors, while dexamethasone has anti-inflammatory and antiemetic effects, and 0.9% NaCl provides hydration and electrolyte balance. Used for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV).
At a glance
| Generic name | palonosetron, dexamethasone, and 0.9% NaCl |
|---|---|
| Also known as | double therapy |
| Sponsor | Sixth Affiliated Hospital, Sun Yat-sen University |
| Drug class | antiemetic combination |
| Target | 5-HT3 receptors, glucocorticoid receptors |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Palonosetron specifically targets 5-HT3 receptors in the central nervous system and gastrointestinal tract to prevent nausea and vomiting. Dexamethasone reduces inflammation and also acts as an antiemetic by modulating the release of inflammatory mediators and affecting the chemoreceptor trigger zone in the brain.
Approved indications
- Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
Common side effects
- Headache
- Constipation
- Dizziness
Key clinical trials
- Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention (NA)
- Triple Therapy for Postoperative Nausea and Vomiting in Laparoscopic Gastrointestinal Surgery (PHASE3)
- A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- palonosetron, dexamethasone, and 0.9% NaCl CI brief — competitive landscape report
- palonosetron, dexamethasone, and 0.9% NaCl updates RSS · CI watch RSS
- Sixth Affiliated Hospital, Sun Yat-sen University portfolio CI
Frequently asked questions about palonosetron, dexamethasone, and 0.9% NaCl
What is palonosetron, dexamethasone, and 0.9% NaCl?
How does palonosetron, dexamethasone, and 0.9% NaCl work?
What is palonosetron, dexamethasone, and 0.9% NaCl used for?
Who makes palonosetron, dexamethasone, and 0.9% NaCl?
Is palonosetron, dexamethasone, and 0.9% NaCl also known as anything else?
What drug class is palonosetron, dexamethasone, and 0.9% NaCl in?
What development phase is palonosetron, dexamethasone, and 0.9% NaCl in?
What are the side effects of palonosetron, dexamethasone, and 0.9% NaCl?
What does palonosetron, dexamethasone, and 0.9% NaCl target?
Related
- Drug class: All antiemetic combination drugs
- Target: All drugs targeting 5-HT3 receptors, glucocorticoid receptors
- Manufacturer: Sixth Affiliated Hospital, Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
- Also known as: double therapy
- Compare: palonosetron, dexamethasone, and 0.9% NaCl vs similar drugs
- Pricing: palonosetron, dexamethasone, and 0.9% NaCl cost, discount & access